Clinical Trials Directory

Trials / Completed

CompletedNCT01381172

Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C

Evaluation of the Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%: FIX-HF-5C

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
160 (actual)
Sponsor
Impulse Dynamics · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this investigation is to evaluate the safety and effectiveness of the OPTIMIZER® System in subjects with medically refractory moderate-to-severe heart failure.

Detailed description

The Impulse Dynamics FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the implantable OPTIMIZER System in patients with NYHA class III and IV heart failure and an ejection fraction 25-45%. The study will involve the recruitment of 160 subjects at a total of up to 60 sites. Those subjects who fulfill all inclusion and exclusion criteria based upon baseline test results will be randomly assigned in a 1:1 ratio to either the OPTIMIZER System plus optimal medical therapy (OMT) or to a control group receiving OMT alone. All randomized subjects will be followed for 24 weeks and shall receive the same study related assessments throughout the course of the study. In addition, all subjects will continue to receive OMT for the treatment of their heart failure. Mortality will be reported out to 2 years.

Conditions

Interventions

TypeNameDescription
DEVICEOptimizer SystemThe OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
OTHERNo intervention: Optimal medical therapyThe control group receives optimal medical therapy only.

Timeline

Start date
2011-01-01
Primary completion
2019-03-19
Completion
2019-03-19
First posted
2011-06-27
Last updated
2021-09-17
Results posted
2021-09-17

Locations

42 sites across 3 countries: United States, Czechia, Germany

Source: ClinicalTrials.gov record NCT01381172. Inclusion in this directory is not an endorsement.